Active Ingredient History
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (approved 2019)
Carcinoma, Hepatocellular (approved 2020)
Carcinoma, Transitional Cell (approved 2016)
Melanoma (approved 2020)
Sarcoma, Alveolar Soft Part (approved 2022)
Small Cell Lung Carcinoma (approved 2019)
Activated Protein C Resistance (Phase 2)
Adenocarcinoma (Phase 2)
Adrenal Gland Neoplasms (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Anus Neoplasms (Phase 3)
Astrocytoma (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 3)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Merkel Cell (Phase 3)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Ovarian Epithelial (Phase 2/Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 2/Phase 3)
Carcinoma, Transitional Cell (Phase 3)
Cholangiocarcinoma (Phase 3)
Chondrosarcoma (Phase 2)
Chordoma (Phase 1/Phase 2)
Circulating Tumor DNA (Phase 2)
Colonic Neoplasms (Phase 3)
Colorectal Neoplasms (Phase 3)
Diabetes Mellitus, Type 2 (Phase 1)
DNA Mismatch Repair (Phase 2)
DNA Repair-Deficiency Disorders (Phase 3)
Drug Therapy (Phase 2)
Endometrial Neoplasms (Phase 3)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 3)
Fallopian Tube Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 3)
Gastrointestinal Neoplasms (Phase 2)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1/Phase 2)
Gliosarcoma (Phase 1/Phase 2)
Hamartoma (Phase 2/Phase 3)
Head and Neck Neoplasms (Phase 2)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 2)
Hypopharyngeal Neoplasms (Phase 2/Phase 3)
Idiopathic Pulmonary Fibrosis (Phase 1)
Immune Checkpoint Inhibitors (Phase 2)
Immunotherapy (Phase 2)
Infusions, Intravenous (Phase 4)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 1/Phase 2)
Kidney Neoplasms (Phase 3)
Laryngeal Neoplasms (Phase 2/Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1/Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)
Liposarcoma (Phase 2)
Liver Neoplasms (Phase 4)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoproliferative Disorders (Phase 2/Phase 3)
Melanoma (Phase 3)
Mesothelin (Phase 1/Phase 2)
Mesothelioma (Phase 3)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 2)
Mouth Neoplasms (Phase 2/Phase 3)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Nasopharyngeal Carcinoma (Phase 2/Phase 3)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2/Phase 3)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 4)
Neoplasms by Histologic Type (Phase 2/Phase 3)
Neoplasms by Site (Phase 2/Phase 3)
Neoplasms, Unknown Primary (Phase 2)
Neoplastic Syndromes, Hereditary (Phase 2)
Neuroendocrine Tumors (Phase 2/Phase 3)
Oncogenes (Phase 2)
Oropharyngeal Neoplasms (Phase 2/Phase 3)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 3)
Penile Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 3)
Pheochromocytoma (Phase 1/Phase 2)
Poly(ADP-ribose) Polymerase Inhibitors (Phase 2)
Prostatic Neoplasms (Phase 3)
Proto-Oncogene Proteins B-raf (Phase 2)
Radiosurgery (Phase 2)
Radiotherapy (Phase 2)
Rectal Neoplasms (Phase 2)
Respiratory Tract Neoplasms (Phase 2)
Rhabdoid Tumor (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Clear Cell (Phase 2)
Sarcoma, Synovial (Phase 2)
Sezary Syndrome (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 3)
Thoracic Neoplasms (Phase 2)
Thrombosis (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Tissues (Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Diseases (Phase 1)
Urinary Bladder Neoplasms (Phase 3)
Urogenital Neoplasms (Phase 2)
Urologic Diseases (Phase 1/Phase 2)
Urologic Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue